目的 利用網(wǎng)絡(luò)藥理學(xué)及分子對(duì)接技術(shù)探索快胃片治療慢性非萎縮性胃炎的作用機(jī)制。方法 利用中藥系統(tǒng)藥理學(xué)數(shù)據(jù)庫(kù)與分析平臺(tái)（TCMSP）和HERB數(shù)據(jù)庫(kù)獲取快胃片的活性成分及其靶點(diǎn)，從GeneCards、OMIM數(shù)據(jù)庫(kù)中獲取慢性非萎縮性胃炎的疾病靶點(diǎn)，取快胃片活性成分及慢性非萎縮性胃炎的交集靶點(diǎn)。通過(guò)STRING數(shù)據(jù)庫(kù)對(duì)交集靶點(diǎn)進(jìn)行蛋白質(zhì)互作分析，Metascape對(duì)交集靶點(diǎn)進(jìn)行基因本體（GO）與京都基因與基因組百科全書（KEGG）富集分析。利用AutodockTools對(duì)快胃片的關(guān)鍵成分及核心靶點(diǎn)進(jìn)行分子對(duì)接初步驗(yàn)證。結(jié)果 網(wǎng)絡(luò)藥理學(xué)研究共獲取152個(gè)快胃片有效活性成分，包括槲皮素、山柰酚、糖蛋白、芒柄花素等，385個(gè)成分靶點(diǎn)，1 082個(gè)慢性非萎縮性胃炎靶點(diǎn)，取交集獲得共同靶點(diǎn)112個(gè)，其中核心靶點(diǎn)為腫瘤蛋白p53（TP53）、腫瘤壞死因子（TNF）、蛋白激酶B1（Akt1）、JUN、白細(xì)胞介素-1β（IL-1β）。GO富集分析顯示生物過(guò)程（BP）有1 650條，主要包括積極調(diào)節(jié)細(xì)胞遷移、對(duì)細(xì)菌源性分子的反應(yīng)、細(xì)胞程序性死亡的正向調(diào)節(jié)；生物功能（MF）有141條，主要包括蛋白激酶結(jié)合、激酶調(diào)節(jié)器活性、細(xì)胞因子受體結(jié)合；細(xì)胞組成（CC）有66條，主要包細(xì)胞外基質(zhì)、膜筏和分泌顆粒腔。KEGG富集分析得到通路188條，主要包括癌癥的發(fā)病途徑、流體剪切應(yīng)力與動(dòng)脈粥樣硬化、IL-17信號(hào)通路、癌癥中的蛋白聚糖、化學(xué)致癌-活性氧等通路。分子對(duì)接結(jié)果顯示快胃片有效成分與核心靶點(diǎn)能夠穩(wěn)定結(jié)合。結(jié)論 快胃片可通過(guò)多成分、多靶點(diǎn)、多通路來(lái)對(duì)慢性非萎縮性胃炎發(fā)揮作用，防止其向慢性萎縮性胃炎轉(zhuǎn)變。

Objective To study the mechanism of Kuaiwei Tablets in treating chronic non-atrophic gastritis based on the methods of network pharmacology and molecular docking technology. Methods The TCMSP database and HERB database were used to obtain the active ingredients and targets of Kuaiwei Tablets, and the disease targets of chronic non-atrophic gastritis were obtained from GeneCards and OMIM databases, and then took the common targets of Kuaiwei Tablets and chronic non-atrophic gastritis. PPI network of the common targets was analysed by STRING database, and GO and KEGG pathway enrichment were analysed by Metascape. AutodockTools was used for molecular docking of the key components and targets of Kuaiwei Tablets. Results A total of 152 active ingredients such as quercetin, kaempferol, glycoprotein, formononetin and so on, 385 ingredient targets, 1 082 targets of chronic non-atrophic gastritis and 112 common targets were obtained from the network pharmacological study. The core targets were TP53, TNF, Akt1, JUN, IL-1β, etc. GO analysis showed that BP (1 650 pieces) mainly involve positive regulation of cell migration, response to molecule of bacterial origin, and positive regulation of programmed cell death, etc. MF (141 pieces) mainly involved kinase binding, kinase regulator activity, and cytokine receptor binding, etc. CC (66 pieces) mainly involved extracellular matrix, membrane raft, and secretory granule lumen, etc. There were 188 pathways obtained in the KEGG enrichment analysis, mainly including pathways in cancer, fluid shear stress and atherosclerosis, IL-17 signaling pathway, proteoglycans in cancer, chemical carcinogenesis-reactive oxygen species, etc. The molecular docking results showed that the effective components of Kuaiwei Tablets and the core targets could combined stably. Conclusion Kuaiwei Tablets can work on CNAG through multi-components, multi-targets and multi-pathways to prevent its transformation to chronic atrophic gastritis.

R285

齊魯醫(yī)派中醫(yī)學(xué)術(shù)流派傳承項(xiàng)目;齊魯傷寒六經(jīng)辨證中醫(yī)藥特色技術(shù)